Antiretroviral therapy in Indian setting: When & what to start with, when & what to switch to?

Indian Journal of Medical Research

Volumn 134, Issue 12, 2011, Pages 787-800

  Kumarasamy, N ^a,c   Patel, Atul ^b,c   Pujari, Sanjay ^c,d  

^a The Voluntary Health Services Chennai   (India)

^b Vedant Institute of Medical Sciences   (India)

^c Institute of Infectious Diseases   (India)

^d HIV Medicine Association of India(HIVMAI)   (India)

Author keywords

Antiretroviral drugs; Antiretroviral therapy; ART; CD4; HIV; IRIS; Viral load

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DELAVERDINE; DIDANOSINE; EFAVIRENZ; ENFUVITRIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; STEROID; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ANOREXIA; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLEEDING; BONE DENSITY; BONE MARROW SUPPRESSION; CONFUSION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG MONITORING; FANCONI RENOTUBULAR SYNDROME; FLATULENCE; GYNECOMASTIA; HEADACHE; HEMOPHILIA; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INDIAN; INSOMNIA; JAUNDICE; KIDNEY FAILURE; LACTIC ACIDOSIS; LIVER TOXICITY; MACROCYTIC ANEMIA; MACULOPAPULAR RASH; NAIL PIGMENTATION; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEUTROPENIA; OSTEOMALACIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; STEROID THERAPY; STEVENS JOHNSON SYNDROME; SYMPTOMATIC ATR; TERATOGENICITY; VIVID DREAM;

EID: 84856586783     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.92626     Document Type: Review

References (167)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Kumarasamy N, Solomon S, Chauguturu S, Cecelia A, Flanigan T, Mayer KH. The changing natural history of HIV disease before and after the introduction of generic antiretroviral therapy in Southern India. Clin Infect Dis 2005; 41: 1525-8.
3. Szczech LA. Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009; 4: 167-70.
4. Brook G, Main J, Nelson M, Bhagani S, Wilkins E, Leen C, et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11: 1-30.
5. Reiberger T, Ferlitsch A, Sieghart W, Kreil A, Breitenecker F, Rieger A, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17: 400-9.
6. Manrique L, Aziz M, Adeyemi OM. Successful immunologic and virologic outcomes in elderly HIV-infected patients. J Acquir Immune Defic Syndr 2010; 54: 332-3.
7. Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging health 2008; 4: 615-27.
8. Bruyand M, Thiebaut R, Lawson-Ayayi S, Joly P, Sasco AJ, Mercié P, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIVinfected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 2009; 49: 1109-16.
9. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 2006; 20: 1117-23.
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
11. Rockstroh J, Guaraldi G, Deray G. HIV and the body: a review of multidisciplinary management. HIV Med 2010; 11 (Suppl 2):1-8.
12. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363: 257-65.
13. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197: 1133-44.
14. Gallant JE. When to start antiretroviral therapy? NA-ACCORD stimulates the debate. AIDS Read 2009; 19: 49-50, 61.
15. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-26.
16. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-404.
17. Grulich AE, Wilson DP. Is antiretroviral therapy modifying the HIV epidemic? Lancet 2010; 376: 1824.
18. Chu C, Selwyn PA. Diagnosis and initial management of acute HIV infection. Am Fam Physician 2010; 81: 1239-44.
19. Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009; 23: 1987-95.
20. Tincati C, Biasin M, Bandera A, Violin M, Marchetti G, Piacentini L, et al. Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther 2009; 14: 321-30.
21. Heaton RK, Clifford DB, Franklin DR Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 2087-96.
22. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ. Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010; 16: 101-14.
23. Njamnshi AK, Bissek AC, Ongolo-Zogo P, Tabah EN, Lekoubou AZ, Yepnjio FN, et al. Risk factors for HIVassociated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaounde-Cameroon. J Neurol Sci 2009; 285: 149-53.
24. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 2008; 24: 1301-7.
25. Rumbaugh JA, Steiner J, Sacktor N, Nath A. Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther 2008; 2: 271-80.
26. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 1915-21.
27. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007; 45: 174-82.
28. Yepthomi T, Paul R, Vallabhaneni S, Kumarasamy N, Tate DF, Solomon S, et al. Neurocognitive consequences of HIV in southern India: a preliminary study of clade C virus. J Int Neuropsychol Soc 2006; 12: 424-30.
29. Almeida JM, Letang E, Nhampossa T, Ayala E, David C, Menendez C, et al. Rapid suppression of HIV-RNA is associated with improved control of immune activation in Mozambican adults initiating antiretroviral therapy with low CD4 counts. AIDS Res Hum Retroviruses 2011; 27: 705-11.
30. Chehimi J, Azzoni L, Farabaugh M, Creer SA, Tomescu C, Hancock A, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol 2007; 179: 2642-50.
31. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370: 407-13.
32. Robbins GK, Spritzler JG, Chan ES, Asmuth DM, Gandhi RT, Rodriguez BA, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48: 350-61.
33. Espinosa E, Ormsby CE, Vega-Barrientos RS, Ruiz-Cruz M, Moreno-Coutiño G, Peña-Jiménez A, et al. Risk factors for immune reconstitution inflammatory syndrome under combination antiretroviral therapy can be aetiology-specific. Int J STD AIDS 2010; 21: 573-9.
34. Orikiiriza J, Bakeera-Kitaka S, Musiime V, Mworozi EA, Mugyenyi P, Boulware DR. The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children. AIDS 2010; 24: 2009-17.
35. Valin N, Pacanowski J, Denoeud L, Lacombe K, Lalande V, Fonquernie L, et al. Risk factors for 'unmasking immune reconstitution inflammatory syndrome' presentation of tuberculosis following combination antiretroviral therapy initiation in HIV-infected patients. AIDS 2010; 24: 1519-25.
36. Mohanty K. Immune reconstitution inflammatory syndrome after initiation of highly active anti-retroviral therapy in HIV/AIDS. Indian J Dermatol Venereol Leprol 2010; 76: 301-4.
37. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 251-61.
38. Uy J, Armon C, Buchacz K, Wood K, Brooks JT. Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 2009; 51: 450-3.
39. Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Moorman AC, Wood KC, et al. Initiation of antiretroviral therapy at CD4 cell counts >/=350 cells/mm3 does not increase incidence or risk of peripheral neuropathy, anemia, or renal insufficiency. J Acquir Immune Defic Syndr 2008; 47: 27-35.
40. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21 (Suppl 4): S117-8.
41. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost-effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 2005; 331: 1431-7.
42. Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, et al. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials 2010; 11: 248-59.
43. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4: e5575.
44. Bicanic T, Jarvis JN, Muzoora C, Harrison TS. Should antiretroviral therapy be delayed for 10 weeks for patients treated with fluconazole for cryptococcal meningitis? Clin Infect Dis 2010; 51: 986-7.
45. Grant PM, Aberg JA, Zolopa AR. Concerns regarding a randomized study of the timing of antiretroviral therapy in zimbabweans with AIDS and acute cryptococcal meningitis. Clin Infect Dis 2010; 51: 984-5.
46. Makadzange AT, Ndhlovu CE, Takarinda K, Reid M, Kurangwa M, Gona P, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50: 1532-8.
47. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365: 1482-91.
48. Karim SA, Knnp AG. Optimal timing of ART during TB therapy: Findings from the SAPiT trial Conf Retroviruses and opportunsitic infections 2011 (Abstr no 39LB). 2011.
49. Lawn SD, Torok ME, Wood R. Optimum time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis 2011; 24: 34-42.
50. Grimes RM, Grimes DE. Readiness: the state of the science (or the lack thereof). Curr HIV/AIDS Rep 2010; 7: 245-52.
51. Grimes RM, Grimes DE. Patient readiness to adhere to HAART. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 364-6.
52. Gebrekristos HT, Mlisana KP, Karim QA. Patients' readiness to start highly active antiretroviral treatment for HIV. BMJ 2005; 331: 772-5.
53. Sierra-Madero J, Villasis-Keever A, Mendez P, Mosqueda-Gómez JL, Torres-Escobar I, Gutiérrez-Escolano F, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr 2010; 53: 582-8.
54. Domingo P, Suarez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 2008; 61: 1348-58.
55. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J et al. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med 2010; 12: 259-68.
56. Boulle A, van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, et al. Outcomes of nevirapine-and efavirenzbased antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-9.
57. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48: 1752-9.
58. Raboud J, Li M, Walmsley S, Cooper C, Blitz S, Bayoumi AM, et al. Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav 2011; 15: 1397-409.
59. Flexner C, Tierney C, Gross R, Andrade A, Lalama C, Eshleman SH, et al. Comparison of once-daily versus twicedaily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis 2010; 50: 1041-52.
60. Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and-experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther 2007; 12: 325-33.
61. Campbell T, Smeaton I, Kumarasamy N, Flanigan T. Efficacy and safety of EFV with either co-formulated 3TC/ZDV or FTC/TDF for initial treatmetn of HIV-1 infected men and women in diverse multinational settings: ACTG PEARLS study conference on retorviruses and opportunistic infections 2011 (abstr no 149LB). 2011.
62. Sanchez-de la Rosa R, Herrera L, Moreno S. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviralnaive, HIV-1-infected patients. Clin Ther 2008; 30: 372-81.
63. Gallant JE, Dejesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
64. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one nonnucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010; 10: CD008740.
65. Gallant JE. Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44: 453-5.
66. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, Flanigan T, et al. Cost-effectiveness of tenofovir as firstline antiretroviral therapy in India. Clin Infect Dis 2010; 50: 416-25.
67. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naive subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. J Acquir Immune Defic Syndr 2009; 52: 209-21.
68. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDs 2008; 22: 337-44.
69. Kumarasamy N, Vallabhneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, et al. Reasons for modification of generic HAART regimens among patients in Southern India. J Acquir Immune Defic Syndr 2006; 41: 53-8.
70. Gallant JE, Moore RD. Renal function with use of a tenofovircontaining initial antiretroviral regimen. AIDS 2009; 23: 1971-5.
71. Ofotokun I, Weitzmann MN. HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes 2010; 17: 523-9.
72. Maserati R, De Silvestri A, Uglietti A, Colao G, Di Biagio A, Bruzzone B, et al. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24: 1013-8.
73. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010; 132: 386-9.
74. Sharma SK. Zidovudine-induced anaemia in HIV/AIDS. Indian J Med Res 2010; 132: 359-61.
75. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C et al. Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010; 53: 215-21.
76. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, et al. Durability of initial antiretroviral therapy in a resource constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010; 53: 215-21.
77. van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, et al. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. PLoS One 2009; 4: e5647.
78. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudineinduced mitochondrial toxicity and myopathy. Pharmacology 2008; 82: 83-8.
79. Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008; 9: 89-95.
80. Castelnuovo B, Kiragga A, Kamya MR, Manabe Y. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. J Acquir Immune Defic Syndr 2011; 56: 59-63.
81. Ribera E, Paradineiro JC, Curran A, Sauleda S, García-Arumí E, Castella E, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008; 9: 407-17.
82. Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007; 45: 261-2.
83. Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol 2009; 47: 2200-8.
84. Borget MY, Diallo K, Adje-Toure C, Chorba T, Nkengasong JN. Virologic and immunologic responses to antiretroviral therapy among HIV-1 and HIV-2 dually infected patients: case reports from Abidjan, Cote d'Ivoire. J Clin Virol 2009; 45: 72-5.
85. Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviralnaive HIV-2-infected patients. AIDS 2009; 23: 1171-3.
86. Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363: 1499-509.
87. Sturmer M, Staszewski S, Doerr HW. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antivir Ther 2007; 12: 695-703.
88. Sturmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, et al. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther 2007; 12: 25-30.
89. Barreiro P, Soriano V. Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. J Antimicrob Chemother 2006; 57: 806-9.
90. Landman R, Descamps D, Peytavin G, Trylesinski A, Katlama C, Girard PM, et al. Early virologic failure and rescue therapy of tenofovir, abacavir, and lamivudine for initial treatment of HIV-1 infection: TONUS study. HIV Clin Trials 2005; 6: 291-301.
91. Jourdain G, Ngo-Giang-Huong N, LeCoeur S. PHPT-3: A randomized clinical trial comparing CD4 vs Viral load ART monitoring/switching startegies in Thailand conference on retroviruses and opportuntistic infections 2011 (abstr no 44). 2011.
92. Kouanfack C, Laurent C, Laborde-Balen G. Monitoring of HIV viral load, CD4 cell count, and clinical monitoring versus clinical monitoring alone for antiretroviral therapy in rural hospitals in Cameroon: Startall ANRS 12110/ESTHER trial, a randomized non-inferiority trial Conf retroviruses and opportunistic infections 2011 (abstr no 45LB). 2011; 11: 825-33.
93. Mugyenyi P, Walker AS, Hakim J, DART Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-31.
94. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43: 436-9.
95. Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, Quinn TC et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009; 14: 293-7.
96. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of firstline highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712-22.
97. Sukasem C, Churdboonchart V, Sukeepaisarncharoen W, Piroj W, Inwisai T, Tiensuwan M et al. Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy. Int J Antimicrob Agents 2008; 31: 277-81.
98. Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E et al. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antivir Ther 2006; 11: 923-9.
99. Vidya M, Saravanan S, Uma S, Kumarasamy N, Sunil SS, Kantor R et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009; 14: 1005-9.
100. Hosseinipour MC, Schechter M. Monitoring antiretroviral therapy in resource-limited settings: balancing clinical care, technology, and human resources. Curr HIV/AIDS Rep 2010; 7: 168-74.
101. Kimmel AD, Weinstein MC, Anglaret X, Goldie SJ, Losina E, Yazdanpanah Y et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54: 258-68.
102. Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clin Infect Dis 2009; 49: 463-5.
103. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosisassociated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-41.
104. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8: 516-23.
105. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10: 791-802.
106. Sidhu N, McCutchan JA. Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J Neuroimmunol 2010; 219: 100-4.
107. Pornprasert S, Leechanachai P, Klinbuayaem V, Leenasirimakul P, Promping C, Inta P et al. Unmasking tuberculosis-associated immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy. Asian Pac J Allergy Immunol 2010; 28: 206-9.
108. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosisassociated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med 2009; 30: 797-810.
109. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-5.
110. Bussone G, Charlier C, Bille E, Caux F, Lévy A, Viard JP et al. Unmasking leprosy: an unusual immune reconstitution inflammatory syndrome in a patient infected with human immunodeficiency virus. Am J Trop Med Hyg 2010; 83: 13-4.
111. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active antiretroviral therapy in Uganda. Afr Health Sci 2008; 8: 190-5.
112. Manosuthi W, Van Tieu H, Mankatitham W, Lueangniyomkul A, Ananworanich J, Avihingsanon A et al. Clinical case definition and manifestations of paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome. AIDS 2009; 23: 2467-71.
113. Biagetti C, Nicola M, Borderi M, Pavoni M, Tampellini L, Verucchi G et al. Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention. New Microbiol 2009; 32: 209-12.
114. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC Jr et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19: 399-406.
115. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42: 418-27.
116. Murdoch DM, Venter WD, Feldman C, Van RA. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22: 601-10.
117. Grant PM, Komarow L, Andersen J, Sereti I, Pahwa S, Lederman MM et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS One 2010; 5: e11416.
118. Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-90.
119. Young B, Buchacz K, Moorman A, Wood KC, Brooks JT. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study. AIDS Patient Care STDs 2009; 23: 589-92.
120. Young B, Buchacz K, Baker RK, et al. Renal function in Tenofovir-exposed and Tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV Outpatient Study. J Int Assoc Physicians AIDS Care (Chic) 2007; 6: 178-87.
121. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008; 83: 265-72.
122. Gallant JE, Winston JA, Dejesus E, Pozniak AL, Chen SS, Cheng AK et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22: 2155-63.
123. De Beaudrap P, Diallo MB, Landman R, Guèye NF, Ndiaye I, Diouf A et al. Changes in the renal function after tenofovircontaining antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 2010; 26: 1221-7.
124. Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341-6.
125. Jhaveri MA, Mawad HW, Thornton AC, Mullen NW, Greenberg RN. Tenofovir-associated severe bone pain: I cannot walk! J Int Assoc Physicians AIDS Care (Chic) 2010; 9: 328-34.
126. Nuesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W et al. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS 2008; 22: 152-4.
127. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther 2005; 10: 615-24.
128. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM et al. Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med 2007; 8: 465-71.
129. Hassan A, Babadoko AA, Mamman AI, Ahmed SA. Zidovudine induced pure red cell aplasia: a case report. Niger J Med 2009; 18: 332-3.
130. Lo JC, Kazemi MR, Hsue PY, Martin JN, Deeks SG, Schambelan M et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005; 41: 1335-40.
131. Hoffmann CJ, Fielding KL, Charalambous S, Sulkowski MS, Innes C, Thio CL et al. Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 2008; 22: 67-74.
132. Bruck S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008; 13: 343-8.
133. Laureillard D, Prak N, Fernandez M, Ngeth C, Moeung S, Riel V et al. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. HIV Med 2008; 9: 514-8.
134. Kumarasamy N, Venkatesh KK, Devaleenal B, Palanivel V, Cecelia AJ, Muthu S et al. Safety of switching to nevirapinebased highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr 2007; 45: 598-600.
135. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, Inthong Y, Prasithsirikul W, Chottanapund S et al. Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. Int J STD AIDS 2007; 18: 782-6.
136. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, Mahasirimongkol S, Sura T, Chantratita W. Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res 2008; 6: 65-9.
137. Manosuthi W, Sungkanuparph S, Tansuphaswadikul S, Chottanapund S, Mankatitham W, Chimsuntorn S et al. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. J Med Assoc Thai 2008; 91: 159-65.
138. Torti C, Lapadula G, Antinori A, Quirino T, Maserati R, Castelnuovo F et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts. Infection 2009; 37: 244-9.
139. Petersen K, Riddle MS, Jones LE, Furtek KJ, Christensen AR, Tasker SA et al. Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy. AIDS 2005; 19: 1700-2.
140. Morello J, Alvarez E, Cuenca L, Vispo E, González-Lahoz J, Soriano V et al. Use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. AIDS Res Hum Retroviruses 2011; 27: 1043-5.
141. Busti AJ, Tsikouris JP, Peeters MJ, Das SR, Canham RM, Abdullah SM et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIVpositive patients. HIV Med 2006; 7: 317-22.
142. Savini C, James C, Wilson S, Martin H, Szabo S, Scotto V. Case presentation: nephrolithiasis in a patient treated with atazanavir. J Assoc Nurses AIDS Care 2008; 19: 225-7.
143. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005; 55: 800-4.
144. Leon A, Martinez E, Sarasa M, López Y, Mallolas J, De Lazzari E et al. Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir/ritonavir-containing therapy free of thymidine analogues. J Antimicrob Chemother 2007; 60: 824-30.
145. Soriano V, Garcia-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008; 61: 200-5.
146. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive HIV-1-infected patients at week 48. AIDS 2008; 22: 1389-97.
147. Estrada V, Fuster M. [Darunavir in treatment-naive patients. The ARTEMIS study]. Enferm Infecc Microbiol Clin 2008; 26 (Suppl 10): 10-3.
148. Hartmann M, Brust J, Schuster D, Mosthaf F, Procaccianti M, Rump JA, et al. [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz]. Hautarzt 2005; 56: 847-53.
149. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
150. Ma JD, Lee KC, Kuo GM. HLA-B*5701 testing to predict abacavir hypersensitivity. PLoS Curr 2010; 2: RRN1203.
151. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother 2007; 59: 591-3.
152. Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy. CNS Drugs 2007; 21 (Suppl 1): 25-30.
153. Monroe A. Understanding and managing peripheral neuropathy. BETA 2010; 22: 27-35.
154. Lugassy DM, Farmer BM, Nelson LS. Metabolic and hepatobiliary side effects of antiretroviral therapy (ART). Emerg Med Clin North Am 2010; 28: 409-19.
155. Waters L, Nelson M. Long-term complications of antiretroviral therapy: lipoatrophy. Int J Clin Pract 2007; 61: 999-1014.
156. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg 2007; 101: 793-8.
157. Mazzotta E, Agostinone A, Rosso R, Di Biagio A, De Socio GV, Cappelletti A, et al. Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case-control study. J Bone Miner Metab 2011.
158. Mary-Krause M, Billaud E, Poizot-Martin I, Simon A, Dhiver C, Dupont C, et al. Risk factors for osteonecrosis in HIV-infected patients: impact of treatment with combination antiretroviral therapy. AIDS 2006; 20: 1627-35.
159. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavirritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58.
160. Yazdanpanah Y, Vray M, Meynard J, Losina E, Weinstein MC, Morand-Joubert L et al. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach. HIV Med 2007; 8: 439-50.
161. Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure. AIDS Patient Care STDs 2007; 21: 544-50.
162. Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. PLoS One 2007; 2: e173.
163. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clin Trials 2005; 6: 183-6.
164. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. J Acquir Immune Defic Syndr 2010; 53: 456-63.
165. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatmentexperienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-12.
166. Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, et al. Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures. J Acquir Immune Defic Syndr 2010; 53: 464-71.
167. Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, Roquebert B, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 2009; 49: 1441-9.